Regeneron Pharmaceuticals, Inc.
REGN
$767.96
$19.252.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.64% | 3.17% | 16.63% | 11.61% | 16.62% |
| Total Depreciation and Amortization | 11.84% | 12.56% | 13.80% | 14.70% | 15.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.75% | 35.26% | -133.15% | -54.29% | -159.55% |
| Change in Net Operating Assets | 174.21% | 65.55% | -980.76% | -557.07% | -269.85% |
| Cash from Operations | 19.39% | 16.53% | -16.58% | -3.78% | -18.70% |
| Capital Expenditure | -5.15% | -19.95% | -26.25% | -5.19% | -30.40% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | -64.77% | 80.80% | 69.95% | 69.95% | 82.78% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 117.48% | 111.41% | 118.28% | 28.85% | 51.50% |
| Cash from Investing | 82.71% | 76.12% | 97.12% | 22.51% | 42.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -86.67% | -74.09% | -37.14% | 27.92% | 37.66% |
| Repurchase of Common Stock | -27.06% | -41.05% | -46.34% | -23.74% | -12.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.16% | -- | -- | -- | -- |
| Cash from Financing | -169.39% | -210.41% | -134.90% | -22.93% | 5.06% |
| Foreign Exchange rate Adjustments | -150.00% | 237.50% | 144.44% | -75.00% | 133.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 437.80% | 506.51% | 136.63% | 34.80% | 88.96% |